
Patrick Forde, MBBCh, PhD, explains why circulating tumor DNA testing falls short after lung cancer surgery and previews vaccine and KRAS G12C trials.

Patrick Forde, MBBCh, PhD, explains why circulating tumor DNA testing falls short after lung cancer surgery and previews vaccine and KRAS G12C trials.

Patrick Forde, MBBCh, PhD, explains how he sequences neoadjuvant and adjuvant osimertinib and why genomic testing matters before lung cancer surgery.

Patrick Forde, MBBCh, PhD, explains how pathological complete response guides his decision to add adjuvant immunotherapy in resectable lung cancer.

Martin Gleave, MD, FRCSC, FACS, discussed selecting patients with high-risk prostate cancer for systemic therapy combined with surgery.

Jeremie Calais, MD, PhD, discussed how biomarkers, disease aggressiveness, and patient preferences informed PSMA-targeted therapy sequencing.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Jeremie Calais, MD, PhD, discussed tailoring PSMA-targeted therapy sequencing and treatment delivery to disease features and response.

Benjamin P. Levy, MD, explains the rationale for dual EGFR and HER3 targeting with iza-bren and the open sequencing questions after osimertinib.

Benjamin P. Levy, MD, explains how patient factors, TP53 co-mutations, and brain metastases guide his first-line choices in EGFR-mutant lung cancer.

Benjamin P. Levy, MD, discusses how osimertinib-based and amivantamab-based combinations are reshaping first-line care for EGFR-mutated non-small cell lung cancer.

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

Welcome to The Show and After-Show with Andrew Svonavec and Kristie L. Kahl, your essential guide to the 43rd Annual Chemotherapy Foundation Symposium (CFS).

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.